Bisphosphonate‐related osteonecrosis of the jaw: an overview
Identifieur interne : 004947 ( Main/Exploration ); précédent : 004946; suivant : 004948Bisphosphonate‐related osteonecrosis of the jaw: an overview
Auteurs : Salvatore L. Ruggiero [États-Unis]Source :
- Annals of the New York Academy of Sciences [ 0077-8923 ] ; 2011-02.
Descripteurs français
- Wicri :
- topic : Chiffre d'affaires.
English descriptors
- KwdEn :
- Acad, Alendronate, American society, Antibiotic therapy, Bisphosphonate, Bisphosphonate exposure, Bisphosphonate therapy, Bisphosphonate treatment, Bisphosphonates, Bone metastases, Bone necrosis, Bone resorption, Bone turnover, Breast cancer, Bronj, Cancer patients, Case series, Chronic bisphosphonate therapy, Clin, Clinical evidence, Complication, Engl, Fracture, Guideline, Intravenous, Intravenous bisphosphonate therapy, Intravenous bisphosphonates, Mandible, Maxillofac, Maxillofacial surgery, Metastasis, Multiple myeloma, Multiple myeloma patients, Myeloma, Necrosis, Necrotic, Necrotic bone, Oncol, Oral bisphosphonates, Oral maxillofac, Oral surg, Osteoclast, Osteoclast function, Osteonecrosis, Osteoporosis, Pamidronate, Pathologic, Pathologic fracture, Postmenopausal osteoporosis, Resorption, Risk factors, Ruggiero, Skeletal complications, Surg, Turnover, York academy, Zolendronic acid.
- Teeft :
- Acad, Alendronate, American society, Antibiotic therapy, Bisphosphonate, Bisphosphonate exposure, Bisphosphonate therapy, Bisphosphonate treatment, Bisphosphonates, Bone metastases, Bone necrosis, Bone resorption, Bone turnover, Breast cancer, Bronj, Cancer patients, Case series, Chronic bisphosphonate therapy, Clin, Clinical evidence, Complication, Engl, Fracture, Guideline, Intravenous, Intravenous bisphosphonate therapy, Intravenous bisphosphonates, Mandible, Maxillofac, Maxillofacial surgery, Metastasis, Multiple myeloma, Multiple myeloma patients, Myeloma, Necrosis, Necrotic, Necrotic bone, Oncol, Oral bisphosphonates, Oral maxillofac, Oral surg, Osteoclast, Osteoclast function, Osteonecrosis, Osteoporosis, Pamidronate, Pathologic, Pathologic fracture, Postmenopausal osteoporosis, Resorption, Risk factors, Ruggiero, Skeletal complications, Surg, Turnover, York academy, Zolendronic acid.
Abstract
Bisphosphonates are widely used in the management of metastatic disease to bone and in diseases of altered bone turnover. Recently, multiple‐case series and retrospective studies have established a relationship between necrotic bone lesions localized to the jaw and the use of chronic bisphosphonate therapy. This condition has been named bisphosphonate‐related osteonecrosis of the jaw (BRONJ). To evaluate the potential risks associated with this new and emerging complication, stage‐specific management strategies and guidelines have been developed. In view of the widespread use of chronic bisphosphonate therapy, the observation of an associated risk of osteonecrosis of the jaw should alert practitioners to monitor for this previously unrecognized complication and to reevaluate the indications for and the duration of bisphosphonate therapy in patients with osteopenia/osteoporosis and cancer. Morbidity associated with BRONJ might be prevented or reduced by implementing prevention strategies and establishing early diagnostic procedures. The current widespread use of bisphosphonates as an inhibitor of bone resorption is directly attributable to their efficacy in improving the quality of life for patients with metastatic bone cancer, osteoporosis, and Paget's disease.
Url:
DOI: 10.1111/j.1749-6632.2010.05768.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 004632
- to stream Istex, to step Curation: 004632
- to stream Istex, to step Checkpoint: 001892
- to stream Main, to step Merge: 004976
- to stream Main, to step Curation: 004947
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bisphosphonate‐related osteonecrosis of the jaw: an overview</title><author><name sortKey="Ruggiero, Salvatore L" sort="Ruggiero, Salvatore L" uniqKey="Ruggiero S" first="Salvatore L." last="Ruggiero">Salvatore L. Ruggiero</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8CF82B7137433579328C8F163C6B0689D34530B3</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1749-6632.2010.05768.x</idno><idno type="url">https://api.istex.fr/document/8CF82B7137433579328C8F163C6B0689D34530B3/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">004632</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004632</idno><idno type="wicri:Area/Istex/Curation">004632</idno><idno type="wicri:Area/Istex/Checkpoint">001892</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001892</idno><idno type="wicri:doubleKey">0077-8923:2011:Ruggiero S:bisphosphonate:related:osteonecrosis</idno><idno type="wicri:Area/Main/Merge">004976</idno><idno type="wicri:Area/Main/Curation">004947</idno><idno type="wicri:Area/Main/Exploration">004947</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Bisphosphonate‐related osteonecrosis of the jaw: an overview</title><author><name sortKey="Ruggiero, Salvatore L" sort="Ruggiero, Salvatore L" uniqKey="Ruggiero S" first="Salvatore L." last="Ruggiero">Salvatore L. Ruggiero</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Oral and Maxillofacial Surgery, School of Dental Medicine, SUNY at Stony Brook, Stony Brook</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Division of Oral and Maxillofacial Surgery, Long Island Jewish Medical Center, New Hyde Park</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Annals of the New York Academy of Sciences</title><title level="j" type="alt">ANNALS OF NEW YORK ACADEMY SCIENCES</title><idno type="ISSN">0077-8923</idno><idno type="eISSN">1749-6632</idno><imprint><biblScope unit="vol">1218</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="38">38</biblScope><biblScope unit="page" to="46">46</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2011-02">2011-02</date></imprint><idno type="ISSN">0077-8923</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0077-8923</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acad</term><term>Alendronate</term><term>American society</term><term>Antibiotic therapy</term><term>Bisphosphonate</term><term>Bisphosphonate exposure</term><term>Bisphosphonate therapy</term><term>Bisphosphonate treatment</term><term>Bisphosphonates</term><term>Bone metastases</term><term>Bone necrosis</term><term>Bone resorption</term><term>Bone turnover</term><term>Breast cancer</term><term>Bronj</term><term>Cancer patients</term><term>Case series</term><term>Chronic bisphosphonate therapy</term><term>Clin</term><term>Clinical evidence</term><term>Complication</term><term>Engl</term><term>Fracture</term><term>Guideline</term><term>Intravenous</term><term>Intravenous bisphosphonate therapy</term><term>Intravenous bisphosphonates</term><term>Mandible</term><term>Maxillofac</term><term>Maxillofacial surgery</term><term>Metastasis</term><term>Multiple myeloma</term><term>Multiple myeloma patients</term><term>Myeloma</term><term>Necrosis</term><term>Necrotic</term><term>Necrotic bone</term><term>Oncol</term><term>Oral bisphosphonates</term><term>Oral maxillofac</term><term>Oral surg</term><term>Osteoclast</term><term>Osteoclast function</term><term>Osteonecrosis</term><term>Osteoporosis</term><term>Pamidronate</term><term>Pathologic</term><term>Pathologic fracture</term><term>Postmenopausal osteoporosis</term><term>Resorption</term><term>Risk factors</term><term>Ruggiero</term><term>Skeletal complications</term><term>Surg</term><term>Turnover</term><term>York academy</term><term>Zolendronic acid</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Alendronate</term><term>American society</term><term>Antibiotic therapy</term><term>Bisphosphonate</term><term>Bisphosphonate exposure</term><term>Bisphosphonate therapy</term><term>Bisphosphonate treatment</term><term>Bisphosphonates</term><term>Bone metastases</term><term>Bone necrosis</term><term>Bone resorption</term><term>Bone turnover</term><term>Breast cancer</term><term>Bronj</term><term>Cancer patients</term><term>Case series</term><term>Chronic bisphosphonate therapy</term><term>Clin</term><term>Clinical evidence</term><term>Complication</term><term>Engl</term><term>Fracture</term><term>Guideline</term><term>Intravenous</term><term>Intravenous bisphosphonate therapy</term><term>Intravenous bisphosphonates</term><term>Mandible</term><term>Maxillofac</term><term>Maxillofacial surgery</term><term>Metastasis</term><term>Multiple myeloma</term><term>Multiple myeloma patients</term><term>Myeloma</term><term>Necrosis</term><term>Necrotic</term><term>Necrotic bone</term><term>Oncol</term><term>Oral bisphosphonates</term><term>Oral maxillofac</term><term>Oral surg</term><term>Osteoclast</term><term>Osteoclast function</term><term>Osteonecrosis</term><term>Osteoporosis</term><term>Pamidronate</term><term>Pathologic</term><term>Pathologic fracture</term><term>Postmenopausal osteoporosis</term><term>Resorption</term><term>Risk factors</term><term>Ruggiero</term><term>Skeletal complications</term><term>Surg</term><term>Turnover</term><term>York academy</term><term>Zolendronic acid</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Chiffre d'affaires</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Bisphosphonates are widely used in the management of metastatic disease to bone and in diseases of altered bone turnover. Recently, multiple‐case series and retrospective studies have established a relationship between necrotic bone lesions localized to the jaw and the use of chronic bisphosphonate therapy. This condition has been named bisphosphonate‐related osteonecrosis of the jaw (BRONJ). To evaluate the potential risks associated with this new and emerging complication, stage‐specific management strategies and guidelines have been developed. In view of the widespread use of chronic bisphosphonate therapy, the observation of an associated risk of osteonecrosis of the jaw should alert practitioners to monitor for this previously unrecognized complication and to reevaluate the indications for and the duration of bisphosphonate therapy in patients with osteopenia/osteoporosis and cancer. Morbidity associated with BRONJ might be prevented or reduced by implementing prevention strategies and establishing early diagnostic procedures. The current widespread use of bisphosphonates as an inhibitor of bone resorption is directly attributable to their efficacy in improving the quality of life for patients with metastatic bone cancer, osteoporosis, and Paget's disease.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Ruggiero, Salvatore L" sort="Ruggiero, Salvatore L" uniqKey="Ruggiero S" first="Salvatore L." last="Ruggiero">Salvatore L. Ruggiero</name></region><name sortKey="Ruggiero, Salvatore L" sort="Ruggiero, Salvatore L" uniqKey="Ruggiero S" first="Salvatore L." last="Ruggiero">Salvatore L. Ruggiero</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004947 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004947 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= EdenteV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8CF82B7137433579328C8F163C6B0689D34530B3
|texte= Bisphosphonate‐related osteonecrosis of the jaw: an overview
}}
| This area was generated with Dilib version V0.6.32. |  |